FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  31 32 33 34 35 36 37 38 39 40 41
 
TXT Outlook Resubmits ONS-5010 BLA
08/30/2022
 
 
TXT Farxiga Phase 3 Data Show Mortality Benefit
08/29/2022
 
 
TXT 2 ICH Guidances on Drug Analytical Procedures
08/26/2022
 
 
TXT Medtronic HVAD Battery Recall is Class 1
08/25/2022
 
 
TXT Novartis Suspends Dosing in Branapalm Trial
08/25/2022
 
 
TXT CGMP Violations at Oregon’s Wild Harvest
08/25/2022
 
 
TXT Steps Toward Drug Quality Knowledge Management System
08/25/2022
 
 
TXT Positive Results in Pfizer RSV Vaccine Trial
08/25/2022
 
 
TXT FDA Approves Abbott Proclaim Plus System
08/25/2022
 
 
TXT FDA Releases 3 Drug Safety-Related Label Changes
08/24/2022
 
 
TXT House Committee on Trump's Covid Pressure on FDA
08/24/2022
 
 
TXT Amazon Warning Letter Raises Questions: Attorneys
08/24/2022
 
 
TXT Pull IPOL Polio Vaccine Until Better Trial Held: ICAN
08/24/2022
 
 
TXT GSK Opposes Teva Coreg ‘Skinny Label’ Appeal
08/23/2022
 
 
TXT Stakeholders Want More Drug Shortage Mitigation Info
08/23/2022
 
 
TXT Ways to Improve FDA Advisory Committee Process
08/23/2022
 
 
TXT FDA Updates eMDR System Enhancements
08/23/2022
 
 
TXT MDIC Somatic Reference Samples Initiative
08/23/2022
 
 
TXT Califf on FDA and the Clinical Community
08/23/2022
 
 
TXT Optical Lens Maker Pays $16.4 Million Over False Claims
08/23/2022
 
 
TXT CDER to Discuss Quality Management Maturity at Meeting
08/22/2022
 
 
TXT Draft Guide on Charging for Investigational Drugs
08/22/2022
 
 
TXT Koag Vascular Closure Pad Cleared
08/22/2022
 
 
TXT NIH’s Fauci Stepping Down At End of Year
08/22/2022
 
 
TXT Medtronic Defibrillator Recall is Class 1
08/19/2022
 
 
TXT FDA Cites Sun Pharma Over GMP Violations
08/19/2022
 
 
TXT Draft Guide on Contact Lens Care Labeling
08/18/2022
 
 
TXT FDA Lifts 1 Emavusertib Clinical Hold
08/18/2022
 
 
TXT FDA Approves Bayer Mirena sNDA
08/18/2022
 
 
TXT CDER Working on Pediatric Extrapolation Framework
08/18/2022
 
 
TXT Medical Device Recalls Up in 2nd Quarter: Sedgwick
08/18/2022
 
 
TXT Radiolabeled Mass Balance Study Comments
08/17/2022
 
 
TXT Final Rule on OTC Hearing Aids
08/17/2022
 
 
TXT Respironics Ventilator MDRs Increase
08/17/2022
 
 
TXT Preceptis Device Cleared for Ear Tube Procedures
08/17/2022
 
 
TXT Makena NDA Withdrawal Hearing 10/17-19
08/16/2022
 
 
TXT Drug Inspections at ‘Operational Levels’: Throckmorton
08/16/2022
 
 
TXT Emergent BioSolutions Warning Letter Out
08/16/2022
 
 
TXT Case Safety Report Transmission Guide
08/16/2022
 
 
TXT Pharma CEO Pleads Guilty to FDA False Statements
08/15/2022
 
 
TXT FDA Extends Review of Reata Pharma NDA
08/09/2022
 
 
TXT Appeals Court Overturns Preemption-related Dismissal
08/08/2022
 
 
TXT Myfembree Wins OK for Endometriosis Pain
08/08/2022
 
 
TXT CDRH Wants Proposals on Device Learning Site Visits
08/05/2022
 
 
TXT Humira ‘Patent Thicket’ Case Dismissal Affirmed
08/04/2022
 
 
TXT Charles River Wants Endotoxin Assay Regulation
08/03/2022
 
 
TXT FDA Working to Cut Ethylene Oxide Emissions
08/03/2022
 
 
TXT Juvéderm Volux XC Approved for Jawline Shaping
08/03/2022
 
 
TXT FDA Approves Cimerli as Generic Lucentis
08/03/2022
 
 
TXT Looking at the FDA/Industry ‘Revolving Door’
08/03/2022
 
 
TXT Alnylam Pharmaceuticals Plans NDA for Patisiran
08/03/2022
 
 
TXT False Claims Liability for Medical Device Off-Label Use
08/03/2022
 
 
TXT Allarity Refocuses in Response to FDA Comments
08/02/2022
 
 
TXT Guide on N-Acetyl-L-Cysteine Enforcement Discretion
08/02/2022
 
 
TXT CDRH Still Working on AL/MI Guidance: Attorneys
08/02/2022
 
 
TXT Priority Review for Gamida’s Omidubicel
08/02/2022
 
 
TXT ImmunityBio Files BLA for Bladder Cancer Therapy
08/01/2022
 
 
TXT Hold Lifted on Celyad Oncology CAR T Therapy
08/01/2022
 
 
TXT AstraZeneca Scraps Monalizumab Clinical Study
08/01/2022
 
 
TXT FTC Endorsement Guides Require Attention: Lawyer
07/29/2022
 
 
TXT Opioid Questions Continue to Dog Califf: AP
07/28/2022
 
 
TXT Share All Cancer Drug Approval Data: Study
07/28/2022
 
 
TXT 3 Lessons Learned from Fosamax ‘Failure-to-Warn’ Case
07/28/2022
 
 
TXT Micro-Organospheres Show Cancer Proof of Concept: NCI
07/28/2022
 
 
TXT Covidien Recalls Palindrome and Mahurkar Catheters
07/28/2022
 
 
TXT Cassava Sciences Under Criminal Investigation: Reuters
07/27/2022
 
 
TXT FDA OKs Bavarian Nordic’s Vaccine Facility
07/27/2022
 
 
TXT Non-Curative Setting Available Therapy
07/27/2022
 
 
TXT Viz.ai Subdural Hemorrhage Detector Cleared
07/27/2022
 
 
TXT Lexicon Re-files NDA for Heart Failure Drug
07/27/2022
 
 
TXT Cannabis Administration and Opportunity Act
07/27/2022
 
 
TXT ‘Objectionable Conditions’ in Goodman Eye Center Trial
07/27/2022
 
 
TXT CGMP Violations in Bi-Coastal Pharma Inspection
07/26/2022
 
 
TXT API Deviations Found at Jost Chemical
07/26/2022
 
 
TXT Avadel Sues FDA Over Lumryz NDA Delay
07/26/2022
 
 
TXT Develop Regulatory Framework for Synthetic Cells: Paper
07/26/2022
 
 
TXT FDA Accepts Biogen Tofersen NDA for Rare ALS
07/26/2022
 
 
TXT FDA Grants Taiho Oncology Lonsurf Petition
07/26/2022
 
 
TXT Many Supplements Stay on Market After FDA Warning
07/26/2022
 
 
TXT Biotronik Pays $13 Million Under False Claims Case
07/25/2022
 
 
TXT Zipperer Debarred by FDA for 5 Years
07/25/2022
 
 
TXT Draft Guide on Real-time Oncology Reviews
07/25/2022
 
 
TXT Compliance Extension Date on Unique Device IDs
07/22/2022
 
 
TXT FDA Proposes to Move to 12-digit National Drug Codes
07/22/2022
 
 
TXT Regulatory Review Didn’t Slow Covid Vaccines: Marks
07/21/2022
 
 
TXT BioCircuit Technologies 510(k) for Nerve Tape
07/21/2022
 
 
TXT Orange Book Therapeutic Equivalence Guide
07/21/2022
 
 
TXT New Renuvion/J-Plasma Handpiece Available: FDA
07/21/2022
 
 
TXT Whitmer Wants Mifepristone REMS Lifted
07/21/2022
 
 
TXT FDA Refusing to Approve ITCA 650
09/02/2021
 
 
TXT Uproar Greets FDA’s Aduhelm OK for Alzheimer’s
06/08/2021
 
 
TXT CGMP Problems at Catalent Pharma Solutions
04/08/2008
 
 
<< Prev  31 32 33 34 35 36 37 38 39 40 41 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving